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Abstract
Background: Neurodegeneration is believed to be the primary cause of permanent, long-term disability in patients
with multiple sclerosis. The cause of neurodegeneration in multiple sclerosis appears to be multifactorial. One
mechanism that has been implicated in the pathogenesis of neurodegeneration in multiple sclerosis is the
targeting of neuronal and axonal antigens by autoantibodies. Multiple sclerosis patients develop antibodies to the
RNA-binding protein, heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1), which is enriched in neurons. We
hypothesized that anti-hnRNP A1 antibodies would contribute to neurodegeneration in an animal model of
multiple sclerosis.
Methods: Following induction of experimental autoimmune encephalomyelitis (EAE) by direct immunization with
myelin oligodendrocyte glycoprotein, mice were injected with anti-hnRNP A1 or control antibodies. Animals were
examined clinically, and the central nervous system (CNS) tissues were tested for neurodegeneration with
Fluoro-Jade C, a marker of degenerating neural elements.
Results: Injection of anti-hnRNP A1 antibodies in mice with EAE worsened clinical disease, altered the clinical
disease phenotype, and caused neurodegeneration preferentially in the ventral spinocerebellar tract and deep
white matter of the cerebellum in the CNS. Neurodegeneration in mice injected with hnRNP A1-M9 antibodies
compared to control groups was consistent with “dying back” axonal degeneration.
Conclusions: These data suggest that antibodies to the RNA-binding protein hnRNP A1 contribute to
neurodegeneration in immune-mediated disease of the CNS.
Keywords: RNA-binding protein, Multiple sclerosis, hnRNP A1, Neurodegeneration, Experimental autoimmune
encephalomyelitis
Background
Neurodegeneration, including neuronal and axonal dam-
age, has been shown to contribute to the pathogenesis of
multiple sclerosis (MS) [1–6]. Manifestations of neuro-
degeneration have been observed using neuroradiologi-
cal, neuropathological, and animal studies of MS. For
example, magnetic resonance imaging (MRI) brain im-
ages of MS patients show axonal damage as well as brain
and spinal cord atrophy, which correlate with neuro-
logical disability [7, 8]. Pathologically, accumulation of
amyloid precursor protein (APP) [9, 10] and staining for
non-phosphorylated neurofilament [3] (both markers of
axonal injury) showed that axonal damage is a major
component of MS lesions [3, 5, 11, 12]. Importantly, sev-
eral studies have shown the presence of neurodegenera-
tion throughout the disease course of MS, not just
during latter progressive phases of disease, as was
* Correspondence: mlevin@uthsc.edu
1Research Service, VA Medical Center, Memphis, TN, USA
2Department of Neurology, University of Tennessee Health Science Center,
855 Monroe Avenue, Room 415, Memphis, TN 38163, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Douglas et al. Journal of Neuroinflammation  (2016) 13:178 
DOI 10.1186/s12974-016-0647-y
originally thought [5]. In experimental autoimmune en-
cephalomyelitis (EAE), an animal model of MS, data in-
dicate that, as in MS, neuronal and axonal damage are
present throughout the course of the disease and thus
contribute to the neurologic disability [13–15]. Further,
axonopathy is a prominent feature of autoimmune de-
myelinating disease induced by myelin-reactive Th1 or
Th17 cells [16].
Antibody targeting of neuronal and axonal antigens is
one of the several proposed mechanisms that might
underlie neurodegeneration in MS and EAE [17]. For ex-
ample, MS patients develop antibodies to the “axolemma-
enriched fraction”, neurofilaments (NFs), and neurofascin
[18–22]. In mice, immunization with NF-L protein re-
sulted in spastic paraparesis concurrent with spinal cord
axonal degeneration [22, 23]. The mice developed a pro-
inflammatory T cell response and importantly, also devel-
oped antibodies to NF-L and IgG deposits within the
axons of the spinal cord lesions [22, 23]. Further, MS
patients were found to make antibodies to neurofascin
[24, 25], a protein with an isoform present on the axons at
the nodes of Ranvier [24, 25]. Application of these anti-
bodies to hippocampal slice cultures inhibited axonal con-
duction [24, 25]. Following induction of EAE with myelin
oligodendrocyte glycoprotein (MOG)-specific T cells, the
addition of anti-neurofascin antibodies augmented disease
[24, 25].
MS patients (in contrast to healthy controls) have also
been found to develop antibodies to heterogeneous nuclear
ribonucleoprotein A1 (hnRNP A1), a ubiquitously
expressed RNA-binding protein (RBP) that is enriched in
neurons [11, 12, 17, 26–28]. Importantly, RBPs, including
hnRNP A1, regulate RNA metabolism, and dysfunctional
RBPs have been shown to cause neurodegeneration in
amyotrophic lateral sclerosis (ALS) and frontotemporal
lobe dementia (FTLD) [29–31]. The immunodominant epi-
tope of hnRNP A1 recognized by MS IgG was experimen-
tally determined to include “M9”, hnRNP A1’s
nucleocytoplasmic shuttling domain, which is required for
its transport into and out of the nucleus to the cytoplasm
[17, 27, 32, 33]. In an in vitro model of neurodegeneration,
anti-M9 antibodies that bind the MS “M9” immunodomi-
nant epitope caused neurodegeneration (as shown by
Fluoro-Jade C staining), apoptosis, and changes in gene
expression related to hnRNP A1 function and the clin-
ical phenotype of MS patients (i.e., spastic paraparesis
and ataxia) [11, 17, 27]. Anti-M9 antibodies were found
to enter neurons in vitro by utilizing endocytosis, a
mechanism identical to antibodies isolated from ALS
patients and monoclonal antibodies directed at Tau
protein [17, 34–36]. Further, the anti-M9 antibodies
caused the mis-localization of hnRNP A1 from predom-
inantly nuclear to an equal nuclear/cytoplasmic distri-
bution suggesting that the anti-M9 antibodies bound
M9 and disrupted hnRNP A1’s normal trafficking be-
tween the nucleus and cytoplasm [17, 34].
Considering these data, we hypothesized that anti-
hnRNP A1-M9 antibodies might promote neurodegener-
ation in vivo. We tested this hypothesis by injecting
anti-hnRNP A1-M9 antibodies in C57BL/6J mice with
MOG-induced EAE. MOG-C57BL/6J EAE mice develop
chronic disease with very little variation once peak
disease has been achieved. Brown and Sawchenko
meticulously mapped the timing of neurodegeneration
of the entire central nervous system (CNS) using
Fluoro-Jade C, a marker of degenerating neural elements
[13]. We paralleled this paradigm and found that the
anti-M9 antibodies caused neurodegeneration in several
neuronal pathways with a strong clinical correlation with
signs and symptoms of MS patients.
Methods
Animals
C57BL/6J and SJL/J female mice were purchased from
Jackson Laboratories (Bar Harbor, ME). The mice were
11 weeks of age at the experimental onset and were
housed on a 12:12-h light:dark cycle, with standard chow
and water freely available under pathogen-free condi-
tions. A sentinel mouse was present in each room, which
was routinely assessed for mouse-borne illnesses. All
animal procedures were reviewed and approved by the
University of Tennessee and Veterans Affairs Medical
Center—Memphis Institutional Animal Care and Use
Committees.
Experimental design, induction of experimental
autoimmune encephalomyelitis, and antibody injections
For EAE, the mice were divided into four groups. Group
#1 (labeled “control”) consisted of “untouched” mice that
did not receive EAE or injections and were housed
under the same conditions as those mice that received
EAE. Group #2 contained mice that received EAE and
injections of phosphate-buffered saline (PBS) intraperito-
neally (ip). Group #3 received EAE and mouse IgG2b
(isotype control) injections (ip), and group #4 received
EAE and mouse IgG2b anti-hnRNP A1 antibodies ip
(experimental group). The experimental paradigm was
as follows. On day 0, the mice were immunized subcuta-
neously on the back between both the upper and hind
limbs with an epitope of myelin oligodendrocyte glyco-
protein (MOG35–55; 100 μg/mouse), emulsified in
complete Freund’s adjuvant (CFA) containing 400 mg/
ml heat-killed Mycobacterium tuberculosis (H37Ra;
Difco). Pertussis toxin (150 ng) was administered via ip
injection on days 0 and 1. Pertussis toxin and MOG35–
55/CFA were obtained from Hooke Laboratories (cat no.
EK-2110) (Lawrence, MA). The mice were checked daily
for clinical signs of EAE (see clinical scoring section
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below). Upon the first clinical signs, the mice were
injected ip with either PBS, mouse IgG2b (isotype control)
(Millipore MABC006), or mouse anti-hnRNP A1-M9 anti-
bodies (Millipore 04-1469). The epitope of the hnRNP
A1-M9 antibodies overlaps with the immunodominant
epitope of IgG isolated from MS patients [27, 34]. Each
animal received three injections of 100 μg of antibody
per injection on days 0, 2, and 4 from the initial signs
of EAE.
For antibody localization studies, anti-hnRNP A1-M9
and isotype control IgG antibodies were conjugated with
CF680, a near-infrared (nIR) marker, according to the man-
ufacturer’s instructions (Caliper/Perkin Elmer, Waltham).
Individual mice were injected with pertussis (200 ng on day
0), followed by the nIR-labeled antibodies (10 mcg once
intravenously via tail vein) on day 3. Twenty-four hours
later, the animals were sacrificed; CNS tissues were re-
moved and visualized using an in vivo imaging system
(IVIS—Perkin Elmer, SpectrumCT In Vivo Imaging System
128201), per the manufacturer’s instructions.
Clinical scoring
Clinical scoring was adapted from “Appendix A—EAE
scoring guide” found in the protocol of the Active Induc-
tion EAE Kit from Hooke Laboratories (Hooke cat no.
EK-2110). The scoring system is composed of scoring
values ranging from 0 to 5.0 increasing at increments of
0.5. The mice were scored daily throughout the study. A
score of 1.0 indicates a “limp tail” (an initial sign of clinical
disease onset), whereas 5.0 is moribund. The mice with
scores of 4.0 or higher for more than 2 days were eutha-
nized and given a score of 5.0 for the remainder of the
study. Quantification was performed in GraphPad Prism
software. Statistical significance was analyzed by two-
way repeated measures analysis of variance (ANOVA)
(p ≤ 0.05). Bonferroni post-tests were performed when
significant differences were indicated. Additionally, a nota-
tion of whether “spastic gait” was observed in an individ-
ual animal was recorded. Spastic gait was described as
abnormally “stiff” or “flexed” extremities, compared to
“typical” EAE, when mice develop a “limp” or flaccid par-
alysis in which their legs drag.
Tissue preparation and analyses of neurodegeneration by
Fluoro-Jade C staining of degenerating neural elements
The mice were either euthanized by perfusion after two
consecutive days of a 4.0 or higher score or at the end of
the study. Intracardiac perfusion was performed via the
aorta. The mice were perfused with 50 ml of ice-cold
PBS until fluid ran clear, followed by 250 ml of ice-cold
4 % buffered paraformaldehyde. The brains and spinal
cords were extracted and post-fixed in 4 % paraformal-
dehyde for 48 h at 4 °C. The brain tissues were sectioned
at 30 μm utilizing a sliding microtome. The spinal cord
tissue was paraffin embedded and sectioned at 10 μm.
The sections were stained with hematoxylin and eosin
and were used as reference.
Fluoro-Jade C (Millipore AG325) was utilized to label
degenerating neural elements in both fixed, frozen brain
tissue as well as paraffin-embedded, fixed, spinal cord tis-
sue [13, 37]. Fluoro-Jade C is a fluorescein derivative that
selectively stains degenerating neural elements [13, 37].
Fluoro-Jade C histochemistry yields results consistent with
other markers of neurodegeneration including staining of
non-phosphorylated neurofilament heavy-chain subunits
and ultrastructural changes shown by electron microscopy
[38]. In EAE, Fluoro-Jade C appears to stain axons and
terminal-like structures with a strong correlation with
SMI-32 (a marker of non-phosphorylated neurofilament
heavy-chain subunits) in white matter tracts [6]. This was
also confirmed by ultrastructural analyses by electron mi-
croscopy, which showed thinning of myelin sheaths and
severely disordered and occasional empty myelin sheaths
[6]. Fluoro-Jade C stains neuronal cell soma less fre-
quently and robustly compared to SMI-32 [6]. In this
study, the brain and spinal cord sections labeled with
Fluoro-Jade C were analyzed while referencing the Inter-
active Atlas Viewer (atlas.brain-map.org) and Brown and
Sawchenko [13], which contained a comprehensive
Fluoro-Jade C staining map of the entire CNS in MOG35–
55-induced EAE. Quantification of Fluoro-Jade C intensity
was performed using ImageJ software, which calculated
the densitometric mean of fluorescence intensity, using a
method adapted from Burgess et al. [39]. Specifically, for
each group, 10 high power fields from at least three differ-
ent animals (n = 30 measurements per group) were ana-
lyzed. Within each high power field, background
fluorescent intensity was subtracted from the mean fluor-
escent intensity, which resulted in the measurement of de-
generating axons within that field. Thirty different fields
per group (10 high power fields from at least three
animals) were examined, and the mean of these 30
measurements was used to evaluate whether there were
differences between the experimental groups using the
student’s t test.
Results
Anti-hnRNP A1-M9 antibodies exacerbate MOG35–55-in-
duced EAE
Following induction of EAE, the mice were monitored
daily for early clinical signs (limp tail) of EAE. Upon the
first clinical signs of EAE (day 0), the mice were injected
with PBS (injection control), anti-mouse IgG2b (isotype
control), or mouse anti-hnRNP A1-M9 antibodies (100 μg
ip on days 0, 2, and 4, for a total of three injections)
(Fig. 1). Naïve C57BL/6J mice (non-EAE, no injections)
were used as a non-disease control. Anti-hnRNP A1-M9
antibody-treated mice developed statistically worse clinical
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disease compared to all other groups (Fig. 1a). Interest-
ingly, anti-hnRNP A1-M9-treated mice developed a spas-
tic gait at a higher frequency than the control groups
(Fig. 1b, an example). In a typical experiment, 50 % of the
anti-hnRNP A1-M9-injected animals were spastic com-
pared to only 10 % of the mice in other EAE groups. Fur-
thermore, several anti-hnRNP A1-M9 mice had to be
euthanized prior to the end of the study due to the sever-
ity of the spasticity and clinical disease, whereas mice in
the other two groups did not commonly reach a score of
4, which indicates a severe disease state. Additionally, in
contrast to all other groups, some of the anti-hnRNP A1-
M9 mice developed tail lesions (30 % of anti-hnRNP A1
EAE compared to 0 % of PBS or isotype control EAE). Im-
portantly, published studies have associated tail lesions in
EAE with increased disease severity and immune re-
sponses [37]. Taken together, these data indicate that the
anti-M9 antibodies contributed to worse disease and a
change in the phenotype of the mice (spastic compared to
flaccid paralysis).
Anti-hnRNP A1-M9 antibodies cause increased levels of
neurodegeneration of specific CNS pathways in EAE
After observing that anti-hnRNP A1-M9 antibodies
worsened EAE, we hypothesized that the augmented
clinical progression might be related to changes in neu-
rodegeneration in the CNS. To examine this, we stained
the brains and spinal cords of three animals from each
group with Fluoro-Jade C, a marker of degenerating
neural elements. Fluoro-Jade C has been used previously
to map neurodegeneration in the identical active
MOG35–55-induced EAE protocol utilized in these stud-
ies. We compared the data between the groups and used
the map of Fluoro-Jade C neurodegeneration in EAE
published by Brown and Sawchenko as reference [13].
There was very minimal background Fluoro-Jade C
staining of non-neural elements in the spinal cords or
brains of unimmunized (“naïve”, “non-EAE”) animals as
previously described (Figs. 2, 3, and 4, “control”) [13]. In
Fig. 1 Clinical progression of EAE in anti-hnRNP A1-M9-injected mice
compared to controls. a EAE was induced in C57BL/6J mice with active
immunization using MOG35–55. At the first clinical signs of disease
(limp tail) (designated as day 0 in this graph), the mice were
injected with 100 μg of PBS (black), isotype-matched IgG2b (green),
or anti-hnRNP A1-M9 (red) antibodies. Injections were given at days
0, 2, and 4 for a total of three injections (arrows). EAE mice were
scored daily from the disease onset using the following standard
scale: 1—limp tail; 2—hind limb weakness/wobbly gait; 3—hind
limb paralysis; 4—hind limb paralysis/weakness of front limbs; and
5—moribund. Quantification was performed in GraphPad Prism
software. Statistical significance was analyzed by two-way repeated
measures analysis of variance (ANOVA) (p ≤ 0.05). b Anti-hnRNP A1-
M9 antibody-treated mice developed increased spastic paralysis
compared to an isotype control IgG2b and PBS-injected animals,
which develop flaccid paralysis
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the spinal cords of the three EAE groups (PBS, isotype
control IgG, anti-hnRNP A1-M9), we found a similar
distribution of staining (Fig. 2a). Staining dominated in
the ventral spinocerebellar tracts (VSCT) at all levels of
the spinal cord, with lesser amounts in the dorsal spino-
cerebellar tracts (DSCT). There was also a modest de-
gree of staining in the dorsal columns (DC) and
throughout the grey matter (GM) of the spinal cord
(Fig. 2a). In the spinal cord, there were no differences in
the mean densitometric Fluoro-Jade C fluorescence in-
tensity between the three EAE groups (VSCT as an ex-
ample, Fig. 2b).
Examination of the brainstems of these animals re-
vealed neurodegeneration in the VSCT, trapezoid body,
spinal tract of the trigeminal nerve, inferior cerebellar
peduncle, and other structures within the brainstem as
described previously [13] (Fig. 3a). There was an absence
of staining in the superior cerebellar peduncle (SCP).
Neurodegeneration was detected in the cerebral pedun-
cles that continued to include the pyramids (not shown)
in all EAE-induced animals. The cerebral peduncle data
parallels that of Brown and Sawchenko [13], but the pyram-
idal data differs in that there was no reported Fluoro-Jade
C staining in the standard MOG-induced EAE. Both areas
involve the corticospinal system, and these differences may
be related to the length of the experiments (which were
about a week longer in the present experiments). By com-
paring the neurodegeneration in the brainstems of the three
Fig. 2 Fluoro-Jade C staining of the spinal cord. a. Paraffin-embedded sections from the lumbosacral region of the spinal cord were sectioned at
10 μm. The sections were stained for neurodegeneration using the Fluoro-Jade C. There was no staining of neural elements in control (non-EAE) mice.
At low power, the spinal cords from all three EAE groups showed staining that was greater in the white matter tracts than in the gray matter. High-
powered images were taken from representative areas (shown by arrows in the low power view) of the ventral spinocerebellar tract (VSCT), showing
similar levels of Fluoro-Jade C staining. b Quantification of Fluoro-Jade C intensity was performed on 10 images from three animals per experimental
group (30 images per condition). The mean densitometric fluorescence intensity was calculated using ImageJ software, and groups were compared
using the student’s t test. There were no differences in fluorescence intensity in the spinal cords of the three EAE groups. Abbreviations: PBS EAE mice
injected with PBS, IgG EAE mice injected with isotype control IgG2b, Anti-hnRNP A1 EAE mice injected with anti-hnRNP A1-M9 antibodies, DC dorsal
columns, CC central canal, GM central gray matter, WM white matter, VSCT ventral spinocerebellar tract
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EAE groups, it was determined that there was an increase
in Fluoro-Jade C staining in one specific tract, the VSCT, of
the anti-hnRNP A1-M9 antibody-treated mice compared to
the other EAE mice. The distal VSCT of the brainstem as it
entered the cerebellum parallel to the SCP showed in-
creased neurodegeneration in anti-hnRNP A1-M9-treated
mice (Fig. 3a). Quantitative analysis (10 images from each
of the three mice per group) of the mean densitometric
Fluoro-Jade C fluorescence intensity using ImageJ software
confirmed an increase in neurodegeneration in the anti-
hnRNPA1-M9 mice compared to all other groups (Fig. 3b).
The cells of origin of the VSCT are admixed with other
neurons within laminae VII, VIII, and IX of the gray matter
of the lumbosacral spinal cord [40–45]. Some of the neu-
rons are grouped into partially defined nuclei within layer
VII including spinal border cells (SBCs), and the lumbar
and sacral pre-cerebellar nuclei [44, 46]. Axons from these
neurons immediately cross in the spinal cord at their seg-
ment of origin in the ventral white matter. These projec-
tions make up the VSCT, which continues up the spinal
column through the lateral funiculi, followed by the brain-
stem and then enters the cerebellum with the SCP, where
its projections then enter the deep white matter of the cere-
bellum [40–45]. The VSCT is the only afferent tract of the
SCP. With this in mind, we next examined the cerebellum
for changes in neurodegeneration between the three EAE
groups.
We observed large quantities of neurodegeneration in
the deep white matter (arbor vitae) of the cerebellum
(Fig. 4). This area contained some of the most intense
Fluoro-Jade C staining of the CNS in EAE [13]. Further-
more, in concordance with the data presented by Brown
Fig. 3 Fluoro-Jade C staining of the ventral spinocerebellar tract of the brainstem. a Fixed, frozen 30-μm brainstem (dorsal medulla) sections were
stained with Fluoro-Jade C. Low-powered images show staining of the ventral spinocerebellar tract (VSCT) with no staining of the superior cerebellar
peduncle (SCP). High-powered images are taken from the area of the VSCT labeled with arrows. b. Quantification of Fluoro-Jade C intensity was
performed on 10 images from three animals per experimental group (30 images per condition). The mean densitometric fluorescence intensity
was calculated using ImageJ software, and groups were compared using the student’s t test. *p≤ 0.05; **p≤ 0.01. CBL cerebellum, 4V 4th ventricle
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and Sawchenko, we also saw a lack of neurodegeneration
in efferent pathways of the cerebellum including
Purkinje cells and the interposed, fastigial, and dentate
nuclei [13]. Comparison of all EAE groups as well as
naive controls revealed that there was increased neuro-
degeneration in the deep white matter (arbor vitae) of
the cerebellum of anti-hnRNP A1-M9 antibody-treated
animals compared to all other EAE groups (Fig. 4a). This
finding was quantified and confirmed using ImageJ soft-
ware, which showed a statistically significant increase in
the mean densitometric Fluoro-Jade C fluorescence in-
tensity in the anti-hnRNP A1-M9 group (Fig. 4b). There
was minimal staining of the granule layer in the cerebel-
lum, none of which included cell bodies. After investi-
gating the brainstem and the cerebellum, we examined
the cerebral cortex for changes in neurodegeneration.
We observed identical patterns of neurodegeneration as
published previously [13].
Gross localization of anti-hnRNP A1-M9 and isotype con-
trol IgG antibodies in mice
To begin to examine how anti-hnRNP A1-M9 anti-
bodies might enter the CNS, we injected mice with
nIR-labelled antibodies and visualized their
localization by IVIS (see the “Methods” section).
Intravenous injection with either antibody showed a min-
imal signal within the CNS structures (Fig. 5c, d). Next,
we injected the mice with pertussis toxin to disrupt the
blood brain/spinal cord barrier, followed by intravenous
injection with either anti-hnRNP A1-M9 or the isotype
control IgG antibodies. In this experiment, the anti-
hnRNP A1-M9 antibodies localized to both the brain and
Fig. 4 Fluoro-Jade C staining of the deep cerebellar white matter (“arbor vitae”). a Fixed, frozen 30-μm sections from the cerebellum were stained with
Fluoro-jade C. Low-powered images show intense staining of the deep cerebellar white matter (wm) with minimal punctate staining of the granule layer
(gr). There was no staining of Purkinje cells (p) or within the molecular layer (m). High-powered images were photographed from within the white matter
(wm) labeled with an asterisk. Arrows represent the borders of the deep white matter of the cerebellum. b Quantification of Fluoro-Jade C intensity was
performed on 10 images from three animals per experimental group (30 images per condition). The mean densitometric fluorescence intensity was
calculated using ImageJ software, and groups were compared using the student’s t test. *p≤ 0.05; ***p ≤0.001
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spinal cord, with the greater signal concentrated in the
spinal cord (Fig. 5a). In contrast, the isotype control IgG
did not localize to the CNS structures (Fig. 5b).
Discussion
These data indicate that in EAE, an animal model of
MS, antibodies to the “M9” sequence of hnRNP A1
(compared to PBS and isotype-matched IgG2b controls)
caused the following: (1) worse clinical disease, (2) an
altered clinical phenotype (spastic paraparesis), and (3)
increased levels of neurodegeneration in the distal pro-
jection of the VSCT and the deep white matter of the
cerebellum. Importantly, antibodies to the CNS targets
have been shown to contribute to neurodegeneration in
MS and EAE [17]. For example, in addition to antibodies
to hnRNP A1-M9, MS patients develop antibodies to
NFs and neurofascin [17, 22, 24, 25]. In mice,
immunization with NF-L caused antibody formation, IgG
deposition on axons, and spastic paraparesis concurrent
with the spinal cord axonal degeneration [22, 23, 47]. In
separate experiments, the addition of anti-neurofascin
antibodies following induction of EAE with MOG-
specific T cells augmented disease and showed in-
creased APP expression [24]. Like antibodies to NF
and neurofascin, the data presented here indicate that
antibodies to hnRNP A1-M9 contribute to neurode-
generation in EAE and because these antibodies are
present in MS patients, strongly support their role in
neurodegeneration in MS [11, 12, 17, 26–28].
Neurodegeneration is now believed to be the primary
cause of permanent, long-term disability in MS patients
[5, 6, 11, 12]. The brains and spinal cords of MS patients
show evidence of both neuronal and axonal degener-
ation. For instance, there is neuronal loss and apoptosis
of cortical pyramidal neurons [48]. In addition, MS brains
display markers of axonal degeneration including axonal
dystrophy, axonal spheroids, and staining for non-
phosphorylated neurofilament (SMI-32) [1–3, 9, 49].
These markers confirm the presence of axonal degener-
ation in MS but do not implicate a specific mechanism
[50]. The cause of neurodegeneration appears to be multi-
factorial. In MS, there is evidence of both “Wallerian
Degeneration”—transection of axons that disconnects the
neuronal cell body from its distal axon and “dying back”
axonopathy—length-dependent, distal to proximal, pro-
gressive axonal degeneration, which occurs in toxic, meta-
bolic, and neurodegenerative diseases [6, 51–53]. Both
involve abnormalities in axonal transport demonstrated by
the accumulation of APP in axons of MS brains, which oc-
curs in the setting of dysfunctional fast axonal transport
[1, 9, 50]. In animal models, axonal degeneration results
from a specific sequence of events, which include im-
paired axonal transport, mitochondrial dysfunction, and
increase in intra-axoplasmic calcium [53, 54]. Importantly,
each of these abnormalities has been found in brains of
MS patients as well as in EAE and have been implicated
in the pathogenesis of neurodegeneration.
Neuroanatomically, we believe the results of these ex-
periments suggest an antibody-mediated autoimmune
response to a CNS target that contributes to “dying
back” axonal degeneration [6, 50, 53, 55]. We examined
the VSCT from caudal to rostral segments starting in the
spinal cord and moving to the brainstem and the cere-
bellum. Specifically, axonal degeneration within the
proximal VSCT in the spinal cord was present in both
control and anti-hnRNP A1-M9 mice. The cells of origin
of the VSCT are contained within laminae VII, VIII, and
IX of the lumbosacral spinal cord; thus, the most
Fig. 5 Localization of anti-hnRNP A1-M9 antibodies and isotype control IgG antibodies in the CNS of mice. Following pertussis injection to disrupt
the blood brain/spinal cord barrier and injection of near IR-labeled anti-hnRNP A1-M9 antibodies, there is a signal consistent with localization of
the antibodies to the brain and spinal cord (a). Under identical conditions, there was a minimal signal using the isotype control IgG (b). Neither
antibody localized to CNS structures without pertussis injection (c, d)
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proximal segments of the VSCT are located in the spinal
cord [40–45]. Moving rostrally, neurodegeneration of
the VSCT continued in both control and anti-hnRNP
A1-M9 mice in the brainstem, but again there were no
differences between the groups. As the VSCT entered
the cerebellum and continued in the arbor vitae (deep
cerebellar white matter), the anti-hnRNP A1-M9 mice
showed significantly worse neurodegeneration than ei-
ther of the control groups. These segments of the VSCT
contain its most distal axons as they synapse on granule
cells in the cerebellum. Considering there are no differ-
ences in proximal, but profound differences in distal seg-
ments of the VSCT, this is consistent with “dying back”
axonal degeneration (Fig. 5) [6, 50, 53, 55]. Importantly,
the VSCT makes afferent connections to the corticosp-
inal tract via cerebellar efferents (Fig. 6). Considering
that both cerebellar lesions and genetic mutations in dis-
eases such as the inherited spastic ataxias cause changes
in muscle tone [56–58], our data suggest that neurode-
generation of the VSCT might also contribute to spasti-
city, which was readily apparent in the anti-hnRNP A1
antibody-injected mice.
Although we believe this to be accurate neuroanatomi-
cally, this study is limited in that (1) we utilized Fluoro-
Jade C, a marker of neurodegeneration that preferentially
labels degenerating neural processes compared to neur-
onal cell bodies (see the “Methods” section), (2) an exact
mechanism explaining this observation is not yet apparent
Fig. 6 Schematic of the anatomical pathways that involve the VSCT. Afferent input from the peripheral nervous system via the (1) dorsal root
ganglia synapse on the cells of origins (neuronal cell bodies) of the (2) VSCT, which are contained within laminae VII, VIII, and IX of lumbosacral
levels of the spinal gray matter. Axons of the (2) VSCT, which are preferentially damaged by the anti-hnRNP A1-M9 antibodies (shown in green),
immediately cross the mid-line of the spinal cord. The (2) VSCT then passes through the brainstem where it enters the cerebellum parallel to the
superior cerebellar peduncle. (2) VSCT axons then pass through the deep cerebellar white matter to synapse on (3) granule cells. (3) Granule cells
synapse on (4) Purkinje cells, which in turn, synapse in (5) the deep cerebellar nuclei. The (5) deep cerebellar nuclei send efferent axons via the
superior cerebellar peduncle to the (6) thalamus, which relays information to the (7) motor cortex, which in turns sends axons that synapse on (8)
anterior horn cells in the ventral gray of the spinal cord. The (2) VSCT (green) showed neurodegeneration from the spinal cord up through to its
distal axons in the deep white matter of the cerebellum, where it was preferentially affected by the anti-hnRNP A1-M9 antibodies consistent with
“dying back” axonal degeneration
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and requires further study, and (3) immune markers in
this model have not yet been examined. Recent data sug-
gest that dying back axonopathy and Wallerian degener-
ation might involve a common pathogenic mechanism.
This was discovered using the mutant slow Wallerian de-
generation (Wlds) mouse [53, 59]. Following nerve injury
in these mice, axonal degeneration was delayed compared
to wild-type controls. The WLDs protein was isolated and
found to be a gain of function mutation [59]. When Wlds
mice were subjected to MOG-induced EAE, neurodegen-
eration was delayed [59, 60]. Further, when the Wlds
mouse was crossed with mouse models of dying back axo-
nopathy in the peripheral nervous system (PNS) (progres-
sive motor neuropathy—Tbce mutation [61] or the
Charcot Marie Tooth (CMT) (type 1B)—MPZ null muta-
tion [62]), degeneration was delayed [59]. In contrast,
there was no effect when crossing Wlds with Plp null
mice. The Plp null mouse is a model of hereditary spastic
paraparesis (HSP) [59, 63], a CNS disorder characterized
by dying back axonopathy. These data suggest that more
than one mechanism may be involved in dying back axo-
nopathy (i.e., PNS vs. CNS). HSP is clinically and patho-
logically similar to progressive forms of MS. Interestingly,
anti-hnRNP A1-M9 antibodies caused neurodegeneration
and altered spinal paraplegia genes (SPG) genes (which
when mutated cause HSP) in an in vitro model of neuro-
degeneration [27].
The mechanism that might cause dying back axonopa-
thy in our model of antibody-mediated neurodegenera-
tion is not yet defined. We believe these data suggest
that the site of attack of the anti-hnRNP A1-M9 anti-
bodies might be the cells of origins (neuronal cell soma)
of the VSCT, which are present in the lumbosacral spinal
cord. Interestingly, anti-hnRNP A1-M9 antibodies local-
ized to the CNS following pertussis injection, suggesting
an entry point for the antibodies (Fig. 5). In further sup-
port of this hypothesis are two recent studies in EAE. The
first showed that the VSCT is one of several pathways that
is preferentially targeted by T cells and activated microglia
early in the course of EAE concurrent with neurodegener-
ation [13]. The second showed that entry of pathogenic
Th1 and Th17 CD4+ T lymphocytes occurs at the L5 lum-
bar level and that the damage present in EAE is initiated
at this level of the CNS [64, 65]. It is possible that both
control and anti-hnRNP A1-M9 antibodies enter the CNS
at L5 of the spinal cord and that the anti-hnRNP A1-M9
antibodies specifically bind to the VSCT cells of origin
(neuronal cell bodies). hnRNP A1 is enriched in large neu-
rons (which contain long axons, like the VSCT) compared
to smaller neurons and glia [28, 66]. Thus, in the milieu of
a pro-inflammatory immune response, which would allow
entry of antibodies into damaged neurons and axons, anti-
hnRNP A1 antibodies could bind hnRNP A1, causing it to
become dysfunctional. Future in vivo antibody tracing
experiment should address the localization of antibodies
in EAE. Interestingly, recent data in our lab using an in
vitro model of neurodegeneration showed that anti-
hnRNP A1-M9 antibodies entered neurons and cause
mis-localization of hnRNP A1 to the cytoplasm where it
co-localized with stress granules and altered RNA metab-
olism of spastin [17, 34, 67]. Changes in spastin metabol-
ism cause spasticity [27, 68], a clinical feature of the
animals in this study. Whether or not spasticity is a result
of dying VSCT axons might not be entirely clear; however,
the results of this study unveil a possible explanation for
the link between neuronal degeneration and spasticity.
Future studies are required to evaluate details of anti-
hnRNP A1-M9 antibodies’ involvement in dying back
axonopathy, Wallerian degeneration, or other mechanisms
of neurodegeneration in autoimmune inflammatory dis-
ease of the CNS.
Conclusions
Anti-hnRNP A1 antibodies contributed to neurodegenera-
tion in an animal model of MS, EAE. Specifically, animals
that received the anti-hnRNP A1 antibodies showed worse
clinical disease and a change in clinical phenotype from
flaccid to spastic paralysis. Further, specific CNS pathways
including the VSCTand the deep white matter of the cere-
bellum underwent preferential neurodegeneration. The
pattern of neurodegeneration was consistent with “dying
back” axonopathy, one of the several mechanisms involved
in the pathogenesis of neurodegeneration in MS. These
data suggest that antibodies to the non-myelin protein,
hnRNP A1, contribute to neurodegeneration in auto-
immune inflammatory disease of the CNS. (Fig. 6 may be
used here.)
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